Teachers Advisors LLC increased its holdings in shares of Alkermes Plc (NASDAQ:ALKS) by 0.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 179,881 shares of the company’s stock after acquiring an additional 1,564 shares during the period. Teachers Advisors LLC owned approximately 0.12% of Alkermes worth $7,634,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of ALKS. Franklin Resources Inc. lifted its stake in shares of Alkermes by 5.1% in the third quarter. Franklin Resources Inc. now owns 4,265,800 shares of the company’s stock worth $181,040,000 after buying an additional 206,300 shares in the last quarter. First Trust Advisors LP lifted its stake in shares of Alkermes by 67.1% in the third quarter. First Trust Advisors LP now owns 2,196,134 shares of the company’s stock worth $93,204,000 after buying an additional 881,946 shares in the last quarter. Thornburg Investment Management Inc. lifted its stake in shares of Alkermes by 1.8% in the third quarter. Thornburg Investment Management Inc. now owns 1,179,492 shares of the company’s stock worth $50,058,000 after buying an additional 21,405 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Alkermes by 3.0% in the second quarter. Northern Trust Corp now owns 876,000 shares of the company’s stock worth $36,056,000 after buying an additional 25,526 shares in the last quarter. Finally, Frontier Capital Management Co. LLC lifted its stake in shares of Alkermes by 3.5% in the third quarter. Frontier Capital Management Co. LLC now owns 707,498 shares of the company’s stock worth $30,026,000 after buying an additional 23,775 shares in the last quarter.

In other Alkermes news, Director David W. Anstice sold 8,787 shares of the company’s stock in a transaction that occurred on Wednesday, December 12th. The shares were sold at an average price of $35.59, for a total transaction of $312,729.33. Following the completion of the sale, the director now directly owns 70,000 shares of the company’s stock, valued at $2,491,300. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Paul J. Mitchell sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, November 2nd. The shares were sold at an average price of $37.51, for a total transaction of $37,510.00. Following the sale, the director now directly owns 8,000 shares of the company’s stock, valued at $300,080. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,787 shares of company stock valued at $416,689. 5.51% of the stock is owned by corporate insiders.

Several research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Alkermes from a “hold” rating to a “buy” rating in a research note on Saturday. JPMorgan Chase & Co. restated a “buy” rating on shares of Alkermes in a research report on Thursday. ValuEngine downgraded shares of Alkermes from a “hold” rating to a “sell” rating in a research report on Wednesday, January 2nd. Goldman Sachs Group downgraded shares of Alkermes from a “neutral” rating to a “sell” rating and lowered their price objective for the company from $49.00 to $26.00 in a research report on Tuesday, December 18th. Finally, Wolfe Research initiated coverage on shares of Alkermes in a research report on Friday, December 14th. They set an “underperform” rating on the stock. Five research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company’s stock. Alkermes presently has an average rating of “Hold” and a consensus target price of $47.36.

Shares of Alkermes stock opened at $32.51 on Monday. The company has a market cap of $5.00 billion, a P/E ratio of -87.86 and a beta of 1.62. Alkermes Plc has a twelve month low of $27.54 and a twelve month high of $71.22. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.56 and a current ratio of 2.85.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Tuesday, October 23rd. The company reported $0.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.15. The company had revenue of $248.72 million for the quarter, compared to the consensus estimate of $236.70 million. Alkermes had a negative net margin of 13.23% and a negative return on equity of 0.12%. The firm’s revenue for the quarter was up 14.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.03 earnings per share. On average, research analysts anticipate that Alkermes Plc will post -0.5 earnings per share for the current fiscal year.

WARNING: This piece of content was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.watchlistnews.com/teachers-advisors-llc-boosts-position-in-alkermes-plc-alks/2744848.html.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes.

See Also: Conference Calls and Individual Investors

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.